(Q43152531)

English

A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma

scientific article published on 23 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 November 2017

A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

14 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

8

object named as

Susan Bates

1 reference

Europe PubMed Central

14 November 2017

9

object named as

Tito Fojo

1 reference

Europe PubMed Central

14 November 2017

Maureen Edgerly

3

object named as

Maureen Edgerly

1 reference

Europe PubMed Central

14 November 2017

author name string

Hui Huang

1

1 reference

Europe PubMed Central

14 November 2017

Michael Menefee

2

1 reference

Europe PubMed Central

14 November 2017

Sen Zhuang

4

1 reference

Europe PubMed Central

14 November 2017

Herb Kotz

5

1 reference

Europe PubMed Central

14 November 2017

Marianne Poruchynsky

6

1 reference

Europe PubMed Central

14 November 2017

Lyn Mickley Huff

7

1 reference

Europe PubMed Central

14 November 2017

language of work or name

0 references

publication date

23 February 2010

1 reference

Europe PubMed Central

14 November 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

14 November 2017

16

1 reference

Europe PubMed Central

14 November 2017

5

1 reference

Europe PubMed Central

14 November 2017

1634-1641

1 reference

Europe PubMed Central

14 November 2017

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence for microtubule target engagement in tumors of patients receiving ixabepilone

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxic chemotherapy for advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rising incidence of renal cell cancer in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epothilones: mechanism of action and biologic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The changing natural history of renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic therapy for renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2007

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20179242

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-09-0379

1 reference

Europe PubMed Central

14 November 2017

1 reference

Europe PubMed Central

14 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43152531&oldid=1982306438"